U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530198) titled 'HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong' on April 01.
Brief Summary: The goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART). The study compares three delivery methods - Teresa -EPT I, PharmaJet Tropis, and PapiVax TriGrid EP - to induce antigen-specific T cell responses in the participants.
The primary objectives are to evaluate the safety of ICVAX delivered using three different devices in the participants within the period Day 0-Day 336, and to evaluat...